EN
EN
FR
ES
PT
AR
RU
DE
IT
NL
TH
KO
VI
ID
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
Synthetic Biology
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium Butyricum and Bifidobacterium Capsule, Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Aflibercept Intravitreous Injection
Denosumab
Enzalutamide Soft Capsules
Sitagliptin Phosphate Tablets
Liraglutide Injection
Sevelamer Carbonate Tablets
Olaparib Tablets
Sorafenib Tablets
Eribulin Mesylate Injection
Neratinib Maleate Tablets
Lenalidomide Capsules
Trastuzumab Injection
Palbociclib Capsules
Semaglutide Injection
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and Innovation
Video Center
Contact
Contact Us
Join Us
NEWS AND INFORMATION
Home
/
Kexing Biopharm...
Kexing Biopharm EU and US GMP Product Introduction-20251023
Article source：
Oct 22,2025
View： 726
LABEL:
< Kexing Biopharm EU and US GMP Product List-20251023
No Next >
BACK TO LIST
Related News
Jun 06,2024
Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone
READ MORE >>
Dec 10,2025
Kexing Biopharm's Licensed-In Product, Infliximab, Receives Marketing Approval in Malaysia
READ MORE >>
Nov 26,2025
Kexing Biopharm's Licensed-In Product, Liraglutide Injection, Successfully Passed Brazil's ANVISA GMP On-Site Audit
READ MORE >>
May 09,2024
Kexing Biopharm Teams Up with Qingfeng Pharma for the Global Market on Olaparib Tablets
READ MORE >>
Jun 13,2025
Kexing Biopharm’s GB18 project received clearance of IND application from NMPA and FDA
READ MORE >>
Apr 09,2024
R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm
READ MORE >>
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
Synthetic Biology
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium Butyricum and Bifidobacterium Capsule, Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Aflibercept Intravitreous Injection
Denosumab
Enzalutamide Soft Capsules
Sitagliptin Phosphate Tablets
Liraglutide Injection
Sevelamer Carbonate Tablets
Olaparib Tablets
Sorafenib Tablets
Eribulin Mesylate Injection
Neratinib Maleate Tablets
Lenalidomide Capsules
Trastuzumab Injection
Palbociclib Capsules
Semaglutide Injection
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and Innovation
Video Center
Contact
Contact Us
Join Us
Article source：
Oct 22,2025
View：
726 
BACK TO LIST
Jun 06,2024
